Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer
NCT01635400
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Carcinoma of Lung
Interventions
DRUG:
Irinotecan
Sponsor
Zhejiang Cancer Hospital